Compositions and methods for detecting human pegivirus 2 (HPgV-2)

• US 9,938,589 B2
• Filed: 07/06/2017
• Issued: 04/10/2018
• Est. Priority Date: 06/27/2014
• Status: Active Grant

• Current Assignee: Abbott Laboratories, Regents of the University of California (University of California)
• Original Assignee: Abbott Laboratories, Regents of the University of California (University of California)
• Inventors: Chiu, Charles, Lee, Deanna, Berg, Michael, Dawson, George, Coller, Kelly, Cheng, Kevin, Hackett, Jr., John R., Frankel, Matthew, Forberg, Kenn
• Primary Examiner(s): Blumel, Benjamin P
• Application Number:
  US15/642,992
• Publication Number:
  US 20170306426A1
• Time in Patent Office: 278 Days
• Field of Search: None
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 49/085 conjugated systems
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2770/24021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2770/24022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2770/24034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12Q 1/701 Specific hybridization probes
• CPC Class Codes: G01N 2333/183 Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
• CPC Class Codes: G01N 2469/20 Detection of antibodies in sample from host which are directed against antigens from microorganisms
• CPC Class Codes: G01N 33/56983 Viruses

Abstract

Provided herein are compositions, methods, and kits for detecting human Pegivirus 2 (HPgV-2). In certain embodiments, provided herein are HPgV-2 specific nucleic acid probes and primers, and methods for detecting HPgV-2 nucleic acid. In other embodiments, provided herein are HPgV-2 immunogenic composition compositions, methods of treating a subject with immunogenic HPgV-2 peptides, and methods of detecting HPgV-2 subject antibodies in a sample.

Claims

1. A method of detecting human Pegivirus 2 (HPgV-2) in a sample comprising:

a) obtaining a biological sample that is from a human patient; and

b) detecting whether HPgV-2 is present in the sample by contacting the sample with an anti-HPgV-2 antibody, or antigen binding portion thereof, and detecting binding between HPgV-2 and the antibody or antigen binding portion thereof.

2. The method of claim 1, wherein said anti-HPgV-2 antibody comprises a monoclonal antibody.

3. The method of claim 1, wherein said antigen binding portion of said anti-HPgV-2 antibody is a F(ab′

)2 fragment, or a Fab fragment.

4. The method of claim 1, wherein said anti-HPgV-2 antibody and/or said antigen binding portion thereof, comprises a detectable label.

5. The method of claim 4, wherein said detectable label comprises an acridinium compound.

6. The method of claim 4, wherein said detectable label comprise streptavidin.

7. The method of claim 4, wherein said detectable label comprises biotin.

8. The method of claim 4, wherein said detectable label is selected from the group consisting of:

a fluorophore, a radioactive moiety, an enzyme, a chromophore, and a chemiluminescent moiety.

9. The method of claim 1, wherein said detecting binding between HPgV-2 and the antibody or antigen binding portion thereof further comprises contacting said sample with a streptavidin labeled solid support, and wherein said anti-HPgV-2 antibody or antigen binding portion thereof comprises a biotin label.

10. The method of claim 9, wherein said solid support comprises microparticles.

11. The method of claim 1, wherein said detecting binding between HPgV-2 and the antibody or antigen binding portion thereof further comprises contacting said sample with a biotin labeled solid support, and wherein said anti-HPgV-2 antibody or antigen binding portion thereof comprises a streptavidin label.

12. The method of claim 11, wherein said solid support comprises microparticles.

13. The method of claim 12, wherein said microparticles are magnetic.

14. The method of claim 1, wherein said detecting binding between HPgV-2 and the antibody or antigen binding portion thereof comprises adding a secondary antibody specific for said anti-HPgV-2 antibody or antigen binding portion thereof.

15. The method of claim 14, wherein said secondary antibody comprises a label.

16. The method of claim 14, wherein said secondary antibody is a monoclonal antibody.

17. The method of claim 1, wherein said biological sample is selected from the group consisting of blood, serum, or plasma.

18. The method of claim 1, wherein said anti-HPgV-2 antibody is specific for a protein selected from the group consisting of:

SEQ ID NOs;

2-11, 76-218, and 304-353.

19. The method of claim 1, wherein said anti-HPgV-2 antibody is specific for a protein shown in SEQ ID NO:

88, 89, or 90.

20. The method of claim 1, wherein said anti-HPgV-2 antibody is specific for a protein shown in SEQ ID NO:

94 or 218.